hrvatski

Urogenitalna atrofija u postmenopauzi

The overall success rate of micronized 17 -estradiol on subjective and objective symptoms of postmenopausal women with vaginal atrophy was 85.5%, and the effect of placebo was 41.4%. A significant improvement of urinary atrophy symptoms was determined in vaginal ERT group comparing with the beginning of the study (51.9% vs. 15.5%, p=0.001). Maximal cystometric capacity and the volume of the urinary bladder at which patients first felt urgency and strong desire to void were considerably larger after micronized 17 -estradiol treatment than before it. The number of patients with uninhibited bladder contractions significantly decreased after micronized 17 -estradiol compared with the values before the treatment or after placebo. Side effects were observed in 61 (7.8%) patients treated with low dose micronized 17- estradiol. We found that 25  g of micronized 17- estradiol do not raise serum estrogen level and do not stimulate endometrial growth.

urogenitalna atrofija; lokalna terapija estrogenima

nije evidentirano